Six studies involving 558 patients showed that FABP5 expression was more strongly associated with OS in patients with digestive tract cancers (OR = 1.619, 95% CI = 1.356, 1.933, p < 0.001, I2 = 0.0%) especially in GC (OR = 1.585, 95% CI = 1.323, 1.899, p < 0.001, I2 = 0.0%), compared to patients with HCC (Table 3, Figure 3A). This evidence concerns the gene FABP5 and hepatocellular carcinoma.